VICENTE LIM: Open Payments
NPI 1275529356 · ROSELLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,174 in 144 payments from 10 companies in 2025. Trend: 2023 $2,076 · 2024 $2,157 · 2025 $2,174
Food & beverage: $2,174
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $391 |
| Neurocrine BioSciences, Inc. | 23 | $352 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $341 |
| ABBVIE INC. | 15 | $218 |
| Alkermes, Inc. | 11 | $199 |
| Luye Pharma (USA) Ltd. | 14 | $191 |
| E.R. Squibb & Sons, L.L.C. | 16 | $181 |
| Janssen Pharmaceuticals, Inc | 10 | $160 |
| Lundbeck LLC | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
Products named: INGREZZA, CAPLYTA, UZEDY, VRAYLAR, ERZOFRI EXTENDED-RELEASE, COBENFY, INVEGA SUSTENNA, ARISTADA.
Industry payments across NJ — which companies pay providers there.
